Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 07-22-2003, 04:23 AM   #1
Paul C.
Posts: n/a
Armed with information about the function and capabilities of currently approved cancer therapies researchers are beginning to develop more potent and successful treatments according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research (AACR). "Scientists have used today's standard drugs to research and develop a new class of effective therapies for cancer sufferers " said Karen Antman M.D. Chief Division of Medical Oncology Columbia University; director of Columbia's Herbert Irving Comprehensive Cancer Center; and AACR president-elect. "These preliminary therapies may increase survival for a number of common cancers."

The "Efficacy of Radioimmunotherapy with Radiolabeled HerceptinTM in Combination with Gemcitabine in the Treatment of Intraperitoneal Disease" is covered in Abstract #5787.

"MAC-321: A Novel Taxane with Greater Efficacy than Paclitaxel and Docetaxel In Vitro and In Vivo" is covered in Abstract #5779.
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 03:36 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter